MGLL and metabolic dysfunction-associated steatotic liver disease: Concurrently, recent investigations have identified acetyl-11-keto-β-boswellic acid (AKBA) as another potent MGLL inhibitor, demonstrating therapeutic potential in addressing non-alcoholic fatty liver disease and its associated metabolic complications, including weight gain and insulin resistance (43).